Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics reported second quarter 2026 financial results with cash, cash equivalents, and investments of $197.2 million, extending the company's operating runway into the first quarter of 2029. The company completed a pre-IND meeting with the FDA for CNTY-813, reaching alignment on the nonclinical data package and Phase 1/2 trial design, keeping the IND submission on track for the fourth quarter of 2026.
Key figures
- Guidance
- Cash runway into 1Q 2029
- Net loss
- 34600000
- Ga expenses
- 5800000
- Rd expenses
- 19600000
- Cash position
- 197200000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.